Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study

Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
doi: https://doi.org/10.1101/2021.10.29.21265248

Article usage

Article usage: October 2021 to March 2023

AbstractFullPdf
Oct 20217880210
Nov 2021184586388
Dec 202142615117
Jan 20222751190
Feb 2022180138
Mar 2022173524
Apr 202293217
May 2022133321
Jun 2022111232
Jul 20225809
Aug 202285223
Sep 2022118313
Oct 202284129
Nov 202253023
Dec 202235223
Jan 202338221
Feb 202367611
Mar 202321420
Back to top
Posted October 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study
Ruvim Izikson, Daniel Brune, Jean-Sébastien Bolduc, Pierre Bourron, Marion Fournier, Tamala Mallett Moore, Aseem Pandey, Lucia Perez, Nessryne Sater, Anju Shrestha, Sophie Wague, Sandrine I Samson
medRxiv 2021.10.29.21265248; doi: https://doi.org/10.1101/2021.10.29.21265248
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area